Agalsidase beta slows the progression of advanced Fabry's disease
This article has no abstract so we have provided the first paragraph of the full text.
Fabry's disease results from a deficiency of the lysosomal enzyme 
-galactosidase A; accumulation of this enzyme's substrates can cause renal, cardiac and cerebrovascular dysfunction, and lead to early death. In this paper, Banikazemi et al. report on a randomized, double-blind, placebo-controlled trial that investigated the effects of agalsidase beta (recombinant -galactosidase A) on clinical outcomes in 82 adult patients with advanced Fabry's disease and mild to moderate kidney dysfunction.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
